Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Zenas BioPharma

Biotech & Life Sciences · Waltham, United States · Founded 2020 · IPO 2024 Thoroughbred

To transform the lives of patients living with autoimmune diseases

Valuation
$861M
Market cap · May/2026
Revenue
$10.0M
Latest reported FY
Featured in $10B+ revenueThoroughbred · Power Law outcome

Investors

20 investors on Zenas BioPharma's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 4 investors entered at this stage
Fairmount Funds Management
Tellus BioVentures
Wellington Management
Quan Capital
Series B+ 16 investors entered at this stage
Superstring Capital
Enavate Sciences
SR One
Delos Capital
Xencor
Rock Springs Capital
Federated Hermes
Pivotal Life Sciences
Agent Capital
Vivo Capital
Norwest Venture Partners
ArrowMark Partners
NEA
Longitude Capital
Perceptive Advisors
Pivotal BioVenture Partners

Global footprint

Where Zenas BioPharma has talent and traffic

Workforce by country
🇺🇸 United States · Waltham HQ
Book a demo for the full country breakdown
Web traffic by country
22K monthly visits
across markets
🇬🇧 United Kingdom64.1%
🇺🇸 United States23.2%
🇨🇦 Canada7.7%
🇯🇵 Japan3.6%
🇮🇱 Israel0.5%
Top 5 markets shown

Market sentiment

What the market is saying about Zenas BioPharma

An AI-synthesized read of the highest-engagement posts about Zenas BioPharma on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Zenas BioPharma on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles